Contact Us
Drug Search Results
More Filters [+]

PEG-BCT-100

Alternative Names: peg-bct-100, pegbct100, peg bct 100, PEG- BCT-100, rhArg1peg5000
Latest Update: 2022-09-02
Latest Update Note: Clinical Trial Update

Product Description

pegylated recombinant human arginase for children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03455140)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PEG-BCT-100

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia|Hepatocellular Carcinoma|Neuroblastoma|Leukemia|Glioma|Sarcoma|Brain Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PARC

P2

Completed

Acute Myeloid Leukemia

2022-07-22

PARC

P2

Unknown status

Glioma|Neuroblastoma|Leukemia|Brain Cancer|Sarcoma

2021-05-01

BCT-100-007

P2

Unknown status

Acute Myeloid Leukemia

2019-09-01

BCT-100-006

P2

Completed

Hepatocellular Carcinoma

2017-03-01

56%

Recent News Events

Date

Type

Title

04/01/2022

PubMed

 A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.

12/01/2021

PubMed

 Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.

10/01/2021

PubMed

 A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions